Observational studyBMC cancer2024

High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.

Kei Furuya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.